Zalicus Halts Rheumatoid Arthritis Drug Trial, Stock Plummets

The stock of Cambridge biotech Zalicus took a 33 percent dive Monday after the company announced it is stopping trials of Synavive, which it had hoped would improve on drugs now on the market to treat rheumatoid arthritis.
Boston Business Journal